Abstracts tagged "Biomarkers"

Abstract Number: 1698 • ACR Convergence 2023
High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis
Huihua Ding, Yiwei Shen, Min Dai and Nan Shen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Navigating the molecular complexity of lupus nephritis (LN), a heterogeneous autoimmune disorder, poses challenges to biomarker discovery. This study addresses these challenges through an…
Abstract Number: 1864 • ACR Convergence 2023
Quantifying Inflammation: A Novel In-Vivo Total Body PET Imaging Tool to Determine the Kinetics of the Degree of Changes in Inflammation in Different Time Points
Siba Raychaudhuri¹, Sanchita Raychaudhuri², Naveen Chandrasekar³, Christine Abria³, Sneha Banerjee³, Smriti K Raychaudhuri³ and Abhijit Chaudhari², ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²UC Davis School of Medicine, Sacramento, CA, ³VA Sacramento Medical Center, Mather, CA
Background/Purpose: Collagen‐induced arthritis (CIA) mouse model is one of the best recognized animal model for autoimmune diseases. In this model clinical methods of evaluating inflammation…
Abstract Number: 2336 • ACR Convergence 2023
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
David Jayne¹, Eduardo Mysler², Zahir Amoura³, Patrick Gavin⁴, Erik Allman⁴, Cristina Di Poto⁴, Xiang Tian⁴, Sonja Hess⁴, Eszter Csomor⁵, Philip Brohawn⁴, Daniel Muthas⁵, Adam Platt⁶, Hussein Al-Mossawi⁶, Catharina Lindholm⁵ and Nicola Ferrari⁶, ¹University of Cambridge, Cambridge, United Kingdom, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³French National Reference Center for SLE, Hôpital La Pitié-Salpêtrière, Paris, France, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…
Abstract Number: 2374 • ACR Convergence 2023
Torque Teno Virus as a Potential Biomarker for Assessment of Immunocompetence in Patients with ANCA-associated Vasculitis
Balazs Odler¹, Regina Riedl¹, Jacinta Lee², Laura Cooney³, Peter Merkel⁴, William St.Clair⁵, Duvuru Geetha⁶, Paul Monach⁷, David Jayne², Rona Smith², Paul A. Lyons², Mark Little⁸, Salem Almaani⁹, Alexander Rosenkranz¹, Ulrich Specks¹⁰, John Stone¹¹ and Andreas Kronbichler¹², ¹Medical University of Graz, Graz, Austria, ²University of Cambridge, Cambridge, United Kingdom, ³Immune Tolerance Network, Seattle, WA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Duke University Medical Center, Durham, NC, ⁶Johns Hopkins University, Baltimore, MD, ⁷VA Boston Healthcare System, Boston, MA, ⁸Trinity College Dublin, Dublin, Ireland, ⁹Ohio State University Medical Center, Columbus, OH, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ¹²Department of Internal Medicine IV (Nephrology and Hypertension), Innsbruck, Austria
Background/Purpose: ANCA-associated vasculitis (AAV) is a life-threatening disorder characterized by a relapsing-remitting disease course necessitating immunosuppression to control disease activity. Balancing the risks of infection…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: 0157 • ACR Convergence 2023
Discovering the Potential of Digital Biomarkers in the Work Process of the Rheumatology Healthcare Professionals, a Design Thinking Approach; Preliminary Results of the Healthcare Professionals Perspective
patty de Groot¹, Jolanda J. Luime¹, Marc r. Kok², marijn vis¹ and ilja Tchetverikov³, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Albert Sweitzer Hospital, Dordrecht, Netherlands
Background/Purpose: During times of social-distancing, in-person outpatient visits were greatly reduced. Health care professionals (HCPs) were dependent on the patient's reported experience of their disease…
Abstract Number: 0548 • ACR Convergence 2023
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Md Yuzaiful Md Yusof¹, Sabih Ul-Hassan¹, Zoe Wigston¹, Antonios Psarras², Jack Arnold¹, Lucy Carter³, Paul Emery⁴ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Oxford University, Oxford, United Kingdom, ³University of Leeds, Hartlepool, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…
Abstract Number: 0666 • ACR Convergence 2023
Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement
Eva Hoekstra¹, Sophie Liem¹, Nivine Levarht¹, Cynthia Fehres¹, Saad Ahmed¹, Nina Ajmone Marsan², Thomas Huizinga¹ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Cardiology, Heart Lung Centre, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: As primary myocardial involvement in systemic sclerosis (SSc) is associated with worse prognosis, research on diagnostic tools for recognition is essential. Troponin I was…
Abstract Number: 0869 • ACR Convergence 2023
Clinical Impact of PTEN as a Marker for Diabetes-Associated Osteoarthritis
Irene Lorenzo Gomez¹, Uxía nogueira Recalde², Christian García Domínguez¹, Natividad Oreiro Villar³, Jose Antonio Pinto Tasende³, Mohit Kapoor⁴, Francisco J. Blanco³ and Beatriz Carames¹, ¹Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (iNIBIC), A Coruña, Spain, ²Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomedica de A Coruña (iNIBIC), A Coruña, Spain, ³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ⁴Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Defects in homeostatic mechanisms, such as autophagy, contribute to joint aging and Osteoarthritis (OA) and precede joint damage (1). OA is a complex and…
Abstract Number: 1171 • ACR Convergence 2023
Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Caoilfhionn M. Connolly¹, Jana Lovell², Melody Chung³, Brittany Adler², Jemima Albayda², Eleni Tiniakou², Christopher Mecoli¹, Stefan Zimmerman², Lisa Christopher-Stine², Nisha Gilotra² and Julie Paik², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Kaiser Permanante, Baltimore, MD
Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its associated morbidity and mortality. As manifestations of myocarditis can be mild or subclinical…
Abstract Number: 1461 • ACR Convergence 2023
Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: MMP-9, S100A8/A9, IL-6, IL-10, and NGAL
Michelle Barraclough¹, Carolina Munoz-Grajales², Lauren Erdman³, Juan Pablo Diaz Martinez⁴, Kathleen Bingham¹, Mahta Kakvan⁵, Roberta Kretzmann⁶, Carmela Tartaglia⁷, Lesley Ruttan⁸, May Choi⁹, Simone Appenzeller¹⁰, Sherief Marzouk⁶, Dennisse Bonilla⁴, Patti Katz¹¹, Dorcas Beaton¹², Anna Goldenberg¹³, Robin Green⁶, Joan Wither¹ and Zahi Touma⁶, ¹University Health Network, Toronto, ON, Canada, ²UHN/TWH, Toronto, ON, Canada, ³Hospital for SickKids, Toronto, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of California San Francisco, San Rafael, CA, ¹²Institute for Work & Health, Toronto, ON, Canada, ¹³Hospital for SickKids, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with SLE [prevalence of 38% (range: 20%-80%)]. The exact mechanisms underlying CI is complex and multifactorial.…
Abstract Number: 1709 • ACR Convergence 2023
Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction
Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
Abstract Number: 1887 • ACR Convergence 2023
Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients
Dario Mazza¹, Siba Raychaudhuri², Yasser Abdelhafez¹ and Abhijit Chaudhari³, ¹University of California Davis, Sacramento, CA, ²UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ³UC Davis School of Medicine, Sacramento, CA
Background/Purpose: To evaluate the ability of total-body PET (TB-PET) biomarkers to quantify enthesitis in Psoriatic (PsA) and Rheumatoid Arthritis (RA). We hypothesize that objective characterization…
Abstract Number: 2337 • ACR Convergence 2023
Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers
Andrew Leber, Raquel Hontecillas, Nuria Tubau Juni and Josep Bassaganya-Riera, NIMML Institute, Blacksburg, VA
Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…
Abstract Number: 2389 • ACR Convergence 2023
Calprotectin (S100A8/S100A9) and Serumamyloid A Are Not Superior to C Reactive Protein and Erythrocyte Sedimentation Rate in Monitoring Disease Activity in Giant Cell Arteritis – Treated with or Without Tocilizumab
Matthias Froehlich¹, Marc Schmalzing², Hannah Labinsky³, Jan Portegys³, Ottar Gadeholt⁴, Patrick-Pascal Strunz¹, Eva C. Schwaneck⁵, Marcus Dittrich⁶, Tobias Mueller⁷ and Michael Gernert³, ¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Würzburg, Würzburg, Germany, ²University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ³Medical Department II, Rheumatology, University Hospital Würzburg, Würzburg, Germany, ⁴Rheumatologische Schwerpunktpraxis Würzburg, Würzburg, Germany, ⁵MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH, Hamburg, Germany, ⁶Department of Bioinformatics, Biocenter, Am Hubland, D-97074 University of Würzburg, Germany ; Institute for Human Genetics, Biocenter, Am Hubland, D-97074 University of Würzburg, Würzburg, Germany, ⁷Department of Bioinformatics, Biocenter, Am Hubland, D-97074 University of Würzburg, Würzburg, Germany
Background/Purpose: Monitoring disease activity in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) remains challenging as standard inflammation parameters, i.e., C-reactive protein (CRP) and erythrocyte…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].